Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA–IIIA non-small-cell lung cancer

被引：4
作者：
Masafumi Kawamura
Keisuke Eguchi
Yotaro Izumi
Yasushi Yamato
Teruaki Koike
Hirozo Sakaguchi
Enjo Hada
Koichi Kobayashi
机构：
[1] Keio University Hospital,Division of General Thoracic Surgery
[2] Niigata Prefectural Cancer Center Hospital,undefined
[3] Mitsui Memorial Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Non-platinum doublet; Adjuvant chemotherapy; Non-small-cell lung cancer; Docetaxel; Gemcitabin; Surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：495 / 501
页数：6
相关论文
共 50 条
  • [41] Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer
    Chen, Chih-Yu
    Wu, Bing-Ru
    Chen, Chia-Hung
    Cheng, Wen-Chien
    Chen, Wei-Chun
    Liao, Wei-Chih
    Chen, Chih-Yi
    Hsia, Te-Chun
    Tu, Chih-Yen
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [42] Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy - A phase II trial
    Tas, F
    Demir, C
    Camlica, H
    Ustuner, Z
    Topuz, E
    [J]. MEDICAL ONCOLOGY, 2004, 21 (03) : 233 - 240
  • [43] Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyA phase II trial
    Faruk Tas
    Cumhur Demir
    Hakan Camlica
    Zeki Ustuner
    Erkan Topuz
    [J]. Medical Oncology, 2004, 21 : 233 - 240
  • [44] A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    [J]. CHEMOTHERAPY, 2005, 51 (2-3) : 120 - 125
  • [45] Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer
    Nakata, M.
    Nojima, Y.
    Nanba, K.
    Saisho, S.
    Shimizu, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S845 - S846
  • [46] A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer
    Okarnoto, Tatsuro
    Yano, Tokujiro
    Shimokawa, Mototsugu
    Takeo, Sadanori
    Yamazaki, Koji
    Sugio, Kenji
    Takenoyama, Mitsuhiro
    Nagashima, Akira
    Tsukamoto, Shuichi
    Hamatake, Motoharu
    Yokoyama, Hideki
    Ueda, Hitoshi
    Motohiro, Akira
    Tagawa, Tetsuzo A.
    Shoj, Fumihiro
    Kometanie, Takuro
    Saito, Genkichi
    Fukuyamap, Yasuro
    Toyokawa, Gouji
    Osoegawa, Atsushi
    Emie, Yasunori
    Maeharaa, Yoshihiko
    [J]. LUNG CANCER, 2018, 124 : 255 - 259
  • [47] Prognostic factors for survival in patients with completely resected pN2 non-small-cell lung cancer
    Sezen, Celal Bugra
    Aksoy, Yunus
    Sonmezoglu, Yasar
    Citak, Necati
    Saydam, Ozkan
    Metin, Muzaffer
    [J]. ACTA CHIRURGICA BELGICA, 2021, 121 (01) : 23 - 29
  • [48] Controversies in the management of stage IIIA non-small-cell lung cancer
    Santos, Edgardo S.
    Castrellon, Aurelio
    Blaya, Marcelo
    Raez, Luis E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1913 - 1929
  • [49] Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer
    Yoshinobu Iwasaki
    Shuji Ohsugi
    Atsushi Natsuhara
    Takuji Tsubokura
    Hidehiko Harada
    Mikio Ueda
    Taichiro Arimoto
    Hiroshi Hara
    Tadaaki Yamada
    Toshiyuki Takesako
    Kenji Kohno
    Shigekuni Hosogi
    Masaki Nakanishi
    Yoshinori Marunaka
    Tsunehiko Nishimura
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 735 - 741
  • [50] A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer
    Teramoto, Koji
    Asada, Yoshikuni
    Ozaki, Yoshitomo
    Suzumura, Yuji
    Nakano, Yasutaka
    Sawai, Satoru
    Tezuka, Noriaki
    Inoue, Shuhei
    Fujino, Shozo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 531 - 537
12345